Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial

The Lancet Infectious Diseases 2026

View at publisher
Authors: Djane C. Baía-da-Silva, Kim Vinícius AmaralC Machado, Amanda Lia RebêloC Rabelo, Antônio AlcirleyC da Silva Balieiro, Antônio S LC Barbosa, Mônica Regina FariasC Costa, Vanderson S Sampaio, Gisely C Melo, Marcia A A Alexandre, Aline C C Alencar, Cristiana Teixeira do Nascimento, Christiane Maria Prado Jerônimo
+16 more Mariana Souza Marcovski, Laila Rowena Albuquerque Barbosa, Cristiane Siqueira do Valle, Thaís Alves Amaral Carrilho, José Luiz Fernandes Vieira, Marly Marques de Melo, Kelry Mazurega Oliveira Dinelly, Aretha Gomes Omena, Jose Diego Brito-Sousa, Gilce Alves Barreiros, Yasmin Vieira Rocha, Aristóteles Comte Alencar Filho, Quique Bassat, Maria das Graças C Alecrim, André Machado Siqueira, Marcus Lacerda
DOI: 10.1016/s1473-3099(26)00139-8
Cited by: 1
References: 25

Fields of Study & Subjects

Malaria Research and Control Pharmaceutical Quality and Counterfeiting Multiple Myeloma Research and Treatments

Publication details

Journal / source
The Lancet Infectious Diseases
Publisher
Elsevier BV
Volume
26
Issue
9
Pages
965–974
Publication date
12 May 2026
Language
EN